The NuvaRing is a form of hormonal contraception that is marketed by its manufacturer as a new form of birth control, one that will make the use of hormonal contraceptives easier for women to use. The NuvaRing is a small, malleable plastic ring that is inserted vaginally.
Over a three week period, the ring releases the hormones progestin and estrogen directly into the bloodstream.
To date, over 1,000 reports have been filed with the FDA regarding the formation of harmful blood clots and deaths connected with the use of the NuvaRing. It is believed by some researchers that the direct release of the hormones estrogen and in particular progestin into the bloodstream leads to a higher risk for blood clots and other health complications linked to blood clots.
Health risks linked to the use of NuvaRing include, but are not limited to, the following:
In May 2012, a Danish study was published in the British Medical Journal. Data from the Danish study demonstrated a significant link between the use of the NuvaRing and the development of blood clots. In fact, the Danish researchers collected data indicating a 90% increased risk of developing blood clots when using the NuvaRing in comparison to other forms of contraceptives, especially when compared to oral contraceptives.
If you or a loved one has suffered from negative side effects linked to the use of the NuvaRing, you and your loved one may be eligible to receive recompense for your suffering. Please know that you do not have to suffer in silence. Many women and their families are standing up against Merck, the manufacturer of the NuvaRing.
The pharmaceutical product liability lawyers at Carey Danis & Lowe have years of experience in litigating national defective medical device lawsuits. For more information about filing a NuvaRing lawsuit, contact an experienced NuvaRing lawyer at Carey Danis & Lowe today.
NuvaRing (Ethinyl Estradiol/Etonogestrel)
Manufacturer: Organon (Merck & Co.)
FDA Approval: October 3, 2001 as contraception to prevent pregnancy
Generic Availability: N/A